27514-07-4

Usage

Uses

Used in Pharmaceutical Synthesis:
7-Azabicyclo[2,2,1]heptane hydrochloride is utilized as a key intermediate in the pharmaceutical industry for the production of various organic compounds. Its unique structure allows it to be a valuable component in the synthesis of new drugs, contributing to the development of innovative therapeutic agents.
Used in Agrochemical Production:
In the agrochemical sector, 7-Azabicyclo[2,2,1]heptane hydrochloride is employed as a fundamental building block in the creation of compounds used in agriculture. Its role in the synthesis of agrochemicals helps to develop products that can improve crop protection and yield.
Used as a Chiral Catalyst in Asymmetric Synthesis:
7-Azabicyclo[2,2,1]heptane hydrochloride is also used as a chiral catalyst in asymmetric synthesis. Its unique structural features make it a promising candidate for facilitating enantioselective reactions, which are critical in producing pharmaceuticals with specific stereochemistry, thereby enhancing the efficacy and safety of the resulting drugs.
Used to Improve Solubility and Stability in Chemical Applications:
The hydrochloride form of 7-Azabicyclo[2,2,1]heptane is commonly used to improve the solubility and stability of the compound in various chemical applications. This enhancement allows for better performance and handling of the compound in different environments, broadening its utility across multiple industries.

InChI:InChI=1/C6H11N.ClH/c1-2-6-4-3-5(1)7-6;/h5-7H,1-4H2;1H

Upstream product

• 27489-62-9 trans-4-hydroxycyclohexylamine 
• 86852-11-1 diethoxyltriphenylphosphorane 
• 279-40-3 7-aza-bicyclo[2.2.1]heptane 
• 111300-06-2 trans-tert-butyl 4-hydroxycyclohexylcarbamate 
• 177545-89-0 (1r,4r)-4-((tert-butoxycarbonyl)amino)cyclohexyl methanesulfonate 
• 1272319-79-5 trans-4-aminocyclohexylmethanesulfonate trifluoroacetic acid salt 
• 27489-62-9 trans-4-aminocyclohexan-1-ol 
• 55258-02-1 7-methyl-7-aza-bicyclo[2.2.1]heptane 
• 343313-51-9 N-(trans-4-hydroxycyclohexyl)-4-methylbenzenesulfonamide 
• 50910-54-8 trans-4-aminocyclohexanol hydrochloride 
• 188624-92-2 7-[(4-methylphenyl)sulfonyl]-7-azabicyclo[2.2.1]heptane 

Downstream Products

• 188624-96-6 N-benzoyl-7-azabicyclo[2.2.1]heptane 
• 643026-80-6 N-(p-cyanobenzoyl)-7-azabicyclo[2.2.1]heptane 
• 204691-94-1 N-(p-toluoyl)-7-azabicyclo[2.2.1]heptane 
• 643026-78-2 N-(p-chlorobenzoyl)-7-azabicyclo[2.2.1]heptane 
• 502925-84-0 N-(p-anisoyl)-7-azabicyclo[2.2.1]heptane 
• 204507-45-9 N-(p-nitrobenzoyl)-7-azabicyclo[2.2.1]heptane 
• 743438-25-7 2-(7-aza-bicyclo[2.2.1]hept-7-yl)-ethanol 
• 1000819-09-9 C₃₂H₄₃N₃O₃S 
• 1190945-83-5 2-[2-[2-(7-azabicyclo[2.2.1]hept-7-yl)-1,1-dimethyl-2-oxoethyl]-5-(3,5-dimethylphenyl)-4H-thieno[3,2-b]pyrrol-6-yl]ethanol 
• 1176870-35-1 2-[4-[2-(7-azabicyclo[2.2.1]hept-7-yl)-1,1-dimethyl-2-oxoethyl]-2-(3,5-dimethylphenyl)-1H-thieno[3,4-b]pyrrol-3-yl]ethanol 
• 1221573-19-8 7-[4-nitro-3-(trifluoromethyl) phenyl]-7-azabicyclo[2.2.1]heptane 
• 1223105-27-8 7-(3-bromo-4-nitrophenyl)-7-azabicyclo[2.2.1]heptane 
• 1223105-25-6 5-(7-azabicyclo[2.2.1]heptan-7-yl)-2-nitrobenzonitrile 
• 1221573-18-7 4-(7-azabicyclo[2.2.1] heptan-7-yl)-2-(trifluoromethyl)aniline 

Relevant academic research and scientific papers

Unexpected resistance to base-catalyzed hydrolysis of nitrogen pyramidal amides based on the 7-azabicyclic[2.2.1]heptane scaffold

Non-planar amides are usually transitional structures, that are involved in amide bond rotation and inversion of the nitrogen atom, but some ground-minimum non-planar amides have been reported. Non-planar amides are generally sensitive to water or other n

CENTRALLY ACTIVE AND ORALLY BIOAVAILABLE ANTIDOTES FOR ORGANOPHOSPHATE EXPOSURE AND METHODS FOR MAKING AND USING THEM

In alternative embodiments, the invention provides nucleophilic hydroxyimino- acetamido alkylamine antidotes that cross the blood-brain barrier (BBB) to catalyze the hydrolysis of organophosphate (OP)-inhibited human acetylcholinesterase (hAChE) in the central nerve system (CNS). The hydroxyimino-acetamido alkylamines of the invention are designed to fit within AChE active center gorge dimensions, bind with reasonable affinity, and react with the conjugated phosphate atom in the gorge. The hydroxyimino- acetamido alkylamines of the invention are also designed to possess ionization states that govern affinity and reactivity for the two linked hAChE re-activation steps. In alternative embodiments, the invention provides pumps, devices, subcutaneous infusion devices, continuous subcutaneous infusion devices, infusion pens, needles, reservoirs, ampoules, a vial, a syringe, a cartridge, a disposable pen or jet injector, a prefilled pen or a syringe or a cartridge, a cartridge or a disposable pen or jet injector, a two chambered or multi- chambered pump, a syringe, a cartridge or a pen or a jet injector, comprising a compound of the invention.

7-Azabicyclo[2.2.1]heptane as a scaffold for the development of selective sigma-2 (σ2) receptor ligands

A series of N-substituted 7-azabicyclo[2.2.1]heptanes (12-17 and 22-25) and similarly substituted pyrrolidines (32-36 and 41-44) were synthesized as sterically-reduced, achiral analogs of adamantane- and trishomocubane-derived σ ligands. In vitro competition binding assays against σ receptors revealed that arylalkyl N-substituents conferred selectivity for the σ2 subtype, while alicyclic or polycarbocyclic substituents imparted high affinity for both subtypes. The σ2 binding and subtype selectivities of N-arylalkyl-7-azanorbornanes was generally greater than the analogously-substituted pyrrolidines, indicating that steric bulk and conformational restriction around the nitrogen atom are likely important for subtype discrimination.

SOLID FORMS OF N-(4-(7-AZABICYCLO[2.2.1]HEPTAN-7-YL)-2-TRIFLUOROMETHYL)PHENYL)-4-OXO-5-(TRIFLUOROMETHYL)-1,4-DIHYDROQUINOLINE-3-CARBOXAMIDE

The present invention relates to substantially crystalline and solid state forms of N-(4-(7-azabicyclo[2.2.1]heptan-7-yl)-2-(trifluoromethyl)phenyl)-4-oxo-5-(trifluoromethyl)-1,4-dihydroquinoline-3-carboxamide (Form A-HCl, Form B, Form B-HCl, or any combination of these forms), pharmaceutical compositions thereof, and methods of treatment therewith.

PROCESS FOR PREPARING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR

The present invention relates to processes for preparing solid state forms of N-(4-(7-azabicyclo[2.2. 1]heptan-7-yl)-2-(trifluoromethyl)phenyl)-4-oxo-5-(trifluoromethyl)-1,4-dihydroquinoline-3-carboxamide, including Compound 1 Form A, Compound 1 Form A- HCl, Compound 1 Form B, and Compound 1 Form B-HCl, any combination of these forms, pharmaceutical compositions thereof, and methods of treatment therewith.

PROCESSES FOR PRODUCING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR

The present invention relates to the process for producing modulators of cystic fibrosis transmembrane conductance regulator (CFTR).

Fischer synthesis of isomeric thienopyrrole LHRH antagonists

As part of a structure-activity exploration into LHRH antagonists, structures containing the thieno[2,3-b]pyrrole core were identified as potent antagonists. This letter describes the employment of the Fischer synthesis to access this thienopyrrole and isomeric final compounds.

THIENOPYROLES AS ANTAGONISTS OF GNRH

The invention relates to a group of novel thieno-pyrrole compounds of Formula (I) wherein: R1, R2, R3, R4 and R5 are as defined in the specification, which are useful as gonadotrophin releasing hormon

PYRROLE DERIVATIVES AS GONADOTROPIN RELEASING HORMONE (GNRH) ANTAGONISTS

The invention relates to a group of novel thieno-pyrrole compounds of formula (I) wherein: R1,R2, R3, R4 M, and R5 are as defined in the specification, as inter alia, gonadotrophin releasing hor

6H-THIENO`2, 3-B!PYRROLE DERIVATIVES AS ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE (GNRH)

The invention relates to a group of novel thieno-pyrrole compounds of Formula (I): wherein: R1, R2, R3, R4 and R5 are as defined in the specification, which are useful as gonadotrophin releasing hormone antagonists. The invention also relates to pharmaceutical formulations of said compounds, methods of treatment using said compounds and to processes for the preparation of said compounds.